CVS
CVS brought the receipts
CVS Health opened the year with a pretty solid flex: first-quarter revenue climbed to $100.4 billion, up 6.2% from a year ago. GAAP diluted EPS came in at $2.30, while adjusted EPS landed at $2.57. Not bad for a company that’s been trying to keep the pharmacy, insurance, and health services juggling act from turning into a three-ring circus.
The real kicker: guidance went up
This is the part investors tend to circle in neon. CVS raised its full-year 2026 outlook, with:
- GAAP diluted EPS guidance now at $6.24 to $6.44, up from $5.94 to $6.14
- Adjusted EPS guidance now at $7.30 to $7.50, up from $7.00 to $7.20
- Cash flow from operations expected to be at least $9.5 billion, versus at least $9.0 billion before
That matters because guidance is basically management saying, “We’re not just surviving the quarter — we think the rest of the year looks better too.” That can support the stock even more than the headline beat.
Why investors should care
CVS is one of those huge, complicated businesses where every percentage point matters. Revenue growth plus higher profit expectations suggests the company is seeing enough strength to lean a little more optimistic, and that can help reset expectations after a choppy stretch in health care and retail.
Big picture: when a company this big raises guidance, it’s rarely just bookkeeping. It’s a signal that the machine is humming a little better than Wall Street feared.